Santaris Acquisition By Roche May Help VCs Back New Biotechs In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.